CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

BACKGROUND: Oral CXC chemokine receptor 2 (CXCR2) antagonists have been shown to inhibit neutrophil migration and activation in the lung in preclinical and human models of neutrophilic airway inflammation. A previous study with danirixin, a reversible CXCR2 antagonist, demonstrated a trend for impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazaar, Aili L., Miller, Bruce E., Donald, Alison C., Keeley, Thomas, Ambery, Claire, Russell, John, Watz, Henrik, Tal-Singer, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291447/
https://www.ncbi.nlm.nih.gov/pubmed/32532258
http://dx.doi.org/10.1186/s12931-020-01401-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291447/
https://www.ncbi.nlm.nih.gov/pubmed/32532258
http://dx.doi.org/10.1186/s12931-020-01401-4

Ejemplares similares